Document is current
Any future updates will be listed below
-
Authors
Modi, Dipenkumar https://orcid.org/0000-0001-6525-8844
Kim, Seongho
Shatta, Maya
Deol, Abhinav https://orcid.org/0000-0003-0947-8871
Kin, Andrew
Ayash, Lois
Ratanatharathorn, Voravit
Uberti, Joseph P.
- License Information
-
More Information
Article History
Received: 9 February 2024
Revised: 7 May 2024
Accepted: 9 May 2024
First Online: 22 May 2024
Competing interests
: Dr. Modi receives research funding from Karyophram, Genmab, ADC therapeutics, Genentech. He served in the advisory board for MorphoSys, ADC therapeutics, Genmab, and Seagen and received financial fees. He received fees for speaker bureau for Beigene. Dr. Deol serves as a Consultant/Advisory board for Adicet, Kite/Gilead and Janssen. Other authors have no existing or potential financial conflict of interest to disclose. Dr. Modi serves in the advisory board in the MorphoSys and Seagen. He receives research funding from Genentech, MorphoSys, Genmab, and ADC Therapeutics, and honorarium from AstraZeneca, Beigene, Genmab, ADC therapeutics, and Seagen. Dr. Deol serves as a Consultant/Advisory board for Adicet, Kite/Gilead and Janssen.
